drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous adoptive cell therapy of neoantigen-selected, tumor‑reactive tumor‑infiltrating lymphocytes (TILs) expanded ex vivo and infused after lymphodepletion with IL‑2 support.
nci_thesaurus_concept_id
C191762
nci_thesaurus_preferred_term
Autologous Tumor Infiltrating Lymphocytes TBio-4101
nci_thesaurus_definition
A preparation of autologous tumor infiltrating lymphocytes (TILs) derived from each patients resected tumor and expanded ex vivo, with potential immunomodulating and antineoplastic activities. Upon administration back into the patient, the autologous TILs TBio-4101 specifically recognize and kill the patients tumor cells.
drug_mesh_term
Toll-Like Receptor 1
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor-infiltrating lymphocytes selected for neoantigen-specific tumor reactivity are expanded ex vivo and reinfused after lymphodepletion. These T cells recognize patient-specific tumor neoantigens via their native TCRs in an MHC-restricted manner and mediate direct cytotoxic killing and cytokine-driven anti-tumor responses; IL-2 support promotes their engraftment, survival, and expansion.
drug_name
TBio-4101
nct_id_drug_ref
NCT05576077